

EXHIBIT 1

U.S. Serial No. 09/666,267

**Copy of Notice to Comply
with Requirements for
Patent Applications
Containing Nucleotide
Sequence and/or Amino
Acid Sequence Disclosures**

Application No.: 09/66626-**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.

2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).

3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).

4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."

5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).

6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).

7. Other: _____

Applicant Must Provide:

An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".

An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

EXHIBIT 2

U.S. Serial No. 09/666,267

Paper copy and computer
readable form of the
Sequence Listing and
Declaration Pursuant to 37
C.F.R. §1.821(f)

SEQUENCE LISTING

<110> Brady, William
Linsley, Peter S.
Ledbetter, Jeffrey A.
Damle, Nitin K.

<120> LIGAND FOR CD28 RECEPTOR ON B CELLS AND METHODS

<130> ON0065C Div 1/30436.11US06

<140> 09/666,267
<141> 2000-09-21

<150> 07/498,949
<151> 1990-03-26

<150> 07/547,980
<151> 1990-07-02

<150> 07/722,101
<151> 1991-06-27

<150> 08/219,200
<151> 1994-03-29

<150> 08/459,766
<151> 1995-06-02

<160> 8

<170> PatentIn version 3.1

<210> 1
<211> 39
<212> DNA
<213> Homo sapiens

<400> 1
ctagccactg aagcttcacc atgggtgtac tgctcacac

39

<210> 2
<211> 39
<212> DNA
<213> Homo sapiens

<400> 2
tggcatgggc tcctgatcag gcttagaagg tccgggaaa

39

<210> 3
<211> 39
<212> DNA
<213> Homo sapi ns

<400> 3

tttgggttcc tgatcaggaa aatgtcttg cttgggtgt

39

<210> 4
<211> 84
<212> DNA
<213> Homo sapiens

<400> 4
aagcaagagc attttcctga tcaggagccc aaatcttctg acaaaaactca cacatccccca

60

ccgtccccag cacctgaact cctg

84

<210> 5
<211> 41
<212> DNA
<213> Homo sapiens

<400> 5
cttcgaccag tctagaagca tcctcgtgcg accgcgagag c

41

<210> 6
<211> 47
<212> DNA
<213> Homo sapiens

<400> 6
cattgcacag tcaagcttcc atgcccattgg gttctctggc caccttg

47

<210> 7
<211> 39
<212> DNA
<213> Homo sapiens

<400> 7
atccacacatg cagtgtatcat ttggatctg gcatgtgac

39

<210> 8
<211> 216
<212> PRT
<213> Homo sapiens

<300>
<301> Gordon J. Freeman, Arnold S. Freedman, Jeffrey M. Segil, Grace Lee, James P. Whitman and Lee M. Nadler
<302> B7, A NEW MEMBER OF THE Ig SUPERFAMILY WITH UNIQUE EXPRESSION ON ACTIVATED AND NEOPLASTIC B CELLS
<303> J. Immunol.
<304> 143
<305> 8
<306> 2714 TO 2722
<307> 1989-10-15
<309>

<313> (1)..(216)

<400> 8

Gly Leu Ser His Phe Cys Ser Gly Val Ile His Val Thr Lys Glu Val
1 5 10 15

Lys Glu Val Ala Thr Leu Ser Cys Gly His Asn Val Ser Val Glu Glu
20 25 30

Leu Ala Gln Thr Arg Ile Tyr Trp Gln Lys Glu Lys Lys Met Val Leu
35 40 45

Thr Met Met Ser Gly Asp Met Asn Ile Trp Pro Glu Tyr Lys Asn Arg
50 55 60

Thr Ile Phe Asp Ile Thr Asn Asn Leu Ser Ile Val Ile Leu Ala Leu
65 70 75 80

Arg Pro Ser Asp Glu Gly Thr Tyr Glu Cys Val Val Leu Lys Tyr Glu
85 90 95

Lys Asp Ala Phe Lys Arg Glu His Leu Ala Glu Val Thr Leu Ser Val
100 105 110

Lys Ala Asp Phe Pro Thr Pro Ser Ile Ser Asp Phe Glu Ile Pro Thr
115 120 125

Ser Asn Ile Arg Arg Ile Ile Cys Ser Thr Ser Gly Gly Phe Pro Glu
130 135 140

Pro His Leu Ser Trp Leu Glu Asn Gly Glu Leu Asn Ala Ile Asn
145 150 155 160

Thr Thr Val Ser Gln Asp Pro Glu Thr Glu Leu Tyr Ala Val Ser Ser
165 170 175

Lys Leu Asp Phe Asn Met Thr Thr Asn His Ser Phe Met Cys Leu Ile
180 185 190

Lys Tyr Gly His Leu Arg Val Asn Gln Thr Phe Asn Trp Asn Thr Thr
195 200 205

Lys Gln Glu His Phe Pro Asp Asn

E

210

215

DKT. 30436.11US06/SBA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Peter S. Linsley et al.
Serial No : 09/666,267
Filed : September 21, 2000
For : LIGAND FOR CD28 RECEPTOR ON B CELLS AND
METHODS

55 S. Lake Avenue, Suite 710
Pasadena, California 91101
July 23, 2003

Mail Stop Sequence
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

SIR:

DECLARATION PURSUANT TO 37 C.F.R. §1.821(f)

I hereby declare that the content of the paper copy and computer readable form of the Sequence Listing initially submitted on September 23, 2002 and December 12, 2003, and the substitute paper copy and computer readable form of the Sequence Listing submitted herewith for the subject patent application in accordance with 37 C.F.R. §1.821(c) and (e), respectively, are the same. I further hereby state that the paper and computer readable copies of the Sequence Listings submitted on September 23, 2002 and December 12, 2003, and the substitute paper copy and computer readable form of the Sequence Listing submitted herewith contain no new matter pursuant to 37 C.F.R. 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d), and are supported by the specification as originally filed.

Respectfully submitted,



Renato Marco P. D. Mingo